Despite an initial favourable response to ADT (achieved by castration), dual heterozygous loss of Pten and Spry2 led to CRPC, signified by comparable tumour burden and overall survival in mock and ADT‐treated mice (Figs 1F and G, and EV1D–F). The gene discussed is SPRY2; the disease is neoplasm.